Rapidly progressing four clinical-stage product candidates, leveraging multiple GLP-1-based mechanisms and routes of administration

Oral ribupatide (KAI-9531-T) is a GLP-1/GIP receptor dual agonist formulated as a once-daily oral tablet in clinical development for the treatment of obesity. An oral version of our extensively studied ribupatide injectable product candidate and based on initial clinical data, oral ribupatide has the potential for compelling weight loss with highly differentiated tolerability among oral obesity management medicines.

KAI-7535 is a once-daily oral small molecule GLP-1 receptor agonist in clinical development for the treatment of obesity. We believe that oral small molecule treatments will play an important role in the treatment of obesity worldwide driven by their convenience and improved scalability, and that KAI-7535 has the potential to offer a competitive weight loss and tolerability profile compared to other oral GLP-1 therapies.

KAI-4729 is a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist in clinical development for the treatment of obesity. KAI-4729 has the potential to offer compelling weight loss, improved liver fat reduction and a differentiated tolerability profile.